respiratori
viru
infect
hematopoiet
cell
transplant
hct
recipi
major
caus
morbid
mortal
respiratori
syncyti
viru
rsv
human
metapneumonviru
parainfluenzavirus
influenza
virus
well
known
potenti
caus
fatal
pneumonia
inform
emerg
recent
signific
newli
discov
virus
human
coronavirus
human
bocaviru
lymphopenia
seem
recent
risk
factor
progress
lower
respiratori
tract
diseas
airflow
obstruct
anoth
complic
respiratori
viru
infect
hct
data
date
indic
complic
may
occur
follow
parainfluenza
viru
rsv
infect
infect
control
procedur
key
prevent
unfortun
random
treatment
studi
make
interpret
literatur
intervent
difficult
articl
review
spectrum
pathogen
epidemiolog
risk
factor
clinic
manifest
infect
well
recent
advanc
diagnost
clinic
manag
immunocompet
person
respiratori
virus
caus
wide
rang
syndrom
syndrom
span
mere
common
cold
episod
incid
croup
bronchiol
airflow
obstruct
children
moreov
respiratori
virus
may
lead
exacerb
asthma
chronic
obstruct
pulmonari
diseas
frank
pneumonia
adult
direct
mortal
rare
associ
virus
immunocompet
peopl
impact
qualiti
life
econom
loss
substanti
contrast
clinic
spectrum
diseas
much
sever
immunocompromis
patient
respiratori
virus
caus
fatal
pneumonia
trigger
late
airflow
obstruct
syndrom
associ
signific
morbid
mortal
chemali
et
al
erard
et
al
ljungman
nichol
et
al
whimbey
et
al
review
summar
current
statu
respiratori
viru
diagnost
diseas
associ
manag
strategi
inform
avail
respiratori
syncyti
viru
rsv
parainfluenza
virus
influenza
virus
probabl
due
fact
virus
readili
identifi
tradit
virolog
detect
method
viral
cultur
immunofluorescencebas
method
recent
describ
human
coronavirus
hcov
human
metapneumoviru
hmpv
human
bocaviru
hbov
well
human
rhinovirus
hrhv
requir
molecular
detect
method
optim
detect
thu
inform
clinic
import
emerg
recent
infect
epidemiolog
respiratori
virus
hct
recipi
usual
parallel
observ
commun
virus
circul
immunocompet
individu
includ
health
care
personnel
famili
member
rsv
influenza
virus
hrhv
hcov
hbov
hmpv
season
distribut
parainfluenza
viru
infect
often
occur
year
around
nonmolecular
method
avail
test
includ
standard
viral
cultur
result
avail
sever
day
shell
vial
centrifug
cultur
use
specif
monoclon
antibodi
result
day
direct
fluoresc
antibodi
test
hour
enzym
immunoassay
hour
tissu
section
lung
biopsi
autopsi
specimen
virusspecif
monoclon
antibodi
stain
viral
cultur
pcr
use
nonmolecular
method
lesser
extent
molecular
detect
method
specimen
acquisit
techniqu
handl
import
maxim
diagnost
yield
nasal
wash
swab
specimen
place
ice
refriger
immedi
transport
laboratori
without
delay
nonmolecular
method
specimen
setup
laboratori
occur
within
hour
signific
shift
toward
molecular
detect
techniqu
recent
year
inde
techniqu
offer
potenti
multiplex
test
platform
lee
et
al
mahoni
et
al
nolt
et
al
import
nonspecif
clinic
present
infect
syndrom
natur
respiratori
viral
infect
ultim
requir
multiplex
test
platform
comprehens
detect
pathogen
sever
assay
describ
literatur
assay
detect
respiratori
virus
shown
excel
perform
characterist
variou
clinic
set
hindiyeh
et
al
kehl
et
al
anoth
multiplex
platform
multicodeplx
system
eragen
bioscienc
inc
madison
wi
detect
respiratori
virus
simultan
show
significantli
increas
diagnost
yield
compar
dfa
cultur
method
mainli
caus
improv
detect
influenza
viru
virus
readili
detect
standard
virolog
method
includ
hmpv
hcov
hrhv
nolt
et
al
viru
microbeadbas
assay
also
show
excel
sensit
specif
well
increas
yield
detect
virus
difficult
detect
cultur
dfa
mahoni
et
al
microarray
nanotechnolog
also
explor
order
develop
largescal
effici
viral
detect
platform
chiu
et
al
fournierwirth
cost
liu
et
al
patient
hematolog
malign
includ
hct
recipi
rsv
caus
upper
respiratori
infect
uri
may
progress
fatal
pneumonia
harrington
et
al
rsv
lower
respiratori
tract
infect
also
link
late
airflow
obstruct
debilit
condit
acceler
loss
lung
function
hct
erard
et
al
respiratori
viru
season
incid
may
high
allogen
autolog
transplant
recipi
may
infect
nichol
et
al
small
et
al
tabl
acquisit
rsv
may
occur
time
transplant
common
patient
outpati
set
one
larg
cohort
studi
winter
season
male
gender
use
bone
marrow
stem
cell
sourc
identifi
acquisit
rsv
hct
recipi
nichol
et
al
uri
preced
pneumonia
patient
approxim
patient
rsv
uri
progress
pneumonia
median
day
howev
patient
rsv
pneumonia
uri
present
mild
occur
concurr
onset
pneumonia
nichol
et
al
strongest
risk
factor
progress
pneumonia
older
age
lymphopenia
nichol
et
al
first
month
hct
patient
receiv
nonmyeloabl
condit
regimen
seem
protect
progress
lower
respiratori
tract
diseas
schiffer
et
al
follow
reduc
intens
condit
regimen
may
also
somewhat
lower
risk
progress
fatal
diseas
chakrabarti
et
al
howev
larger
studi
need
better
defin
risk
progress
studi
indic
asymptomat
shed
rsv
common
phenomenon
adam
et
al
ljungman
et
al
without
treatment
rsv
pneumonia
almost
uniformli
fatal
highli
immunosuppress
hct
recipi
harrington
et
al
howev
recoveri
rsv
lower
respiratori
tract
diseas
without
specif
treatment
report
abdallah
et
al
differ
like
due
less
intens
immunosuppress
regimen
whether
lymphopenia
present
time
diagnosi
chemali
et
al
pulmonari
copathogen
detect
one
third
patient
rsv
pneumonia
requir
aggress
treatment
adequ
power
control
trial
exist
treatment
rsv
infect
pneumonia
hct
set
avail
evid
come
small
uncontrol
cohort
studi
one
small
random
trial
data
suggest
treatment
earli
pneumonia
ie
prior
mechan
ventil
associ
improv
outcom
intermitt
short
durat
g
hour
three
time
per
day
continu
aerosol
ribavirin
consid
treatment
choic
rsv
pneumonia
regimen
allcaus
mortal
approxim
tabl
larg
multivari
analysi
rsv
pneumonia
uri
independ
associ
mortal
nichol
et
al
system
ribavirin
alon
seem
effect
treatment
pneumonia
lewinsohn
et
al
sparrelid
et
al
better
respons
rate
report
treatment
rsv
uri
howev
small
sampl
size
limit
strength
data
schleun
et
al
data
combin
oral
aerosol
ribavirin
role
concomit
intraven
immunoglobulin
rsvspecif
immunoglobulin
palivizumab
rsvspecif
monoclon
antibodi
direct
f
protein
rsv
treatment
rsv
pneumonia
poorli
defin
uncontrol
data
suggest
hightit
antibodi
prepar
palivizumab
may
requir
adjunct
therapi
given
boeckh
et
al
devincenzo
et
al
small
et
al
sever
factor
may
account
differ
outcom
avail
cohort
studi
one
import
factor
appear
time
initi
therapi
sever
studi
suggest
treatment
start
respiratori
failur
occur
almost
uniformli
unsuccess
whimbey
et
al
factor
may
explain
differ
outcom
studi
includ
presenc
lymphopenia
time
diagnosi
presenc
copathogen
eg
invas
mould
use
immunosuppress
agent
chemali
et
al
ljungman
avail
studi
small
control
paramet
make
interpret
result
pharmacolog
intervent
difficult
center
agre
aerosol
ribavirin
given
hct
patient
rsv
lower
respiratori
tract
diseas
consensu
role
antibodi
prepar
howev
author
use
palivizumab
radiograph
virolog
proven
rsv
pneumonia
due
high
mortal
rsv
pneumonia
much
interest
focus
prevent
recent
small
control
studi
preemptiv
antivir
therapi
aerosol
ribavirin
given
time
rsv
uri
show
declin
viral
load
signific
differ
rsv
pneumonia
studi
prematur
stop
due
slow
accrual
larger
retrospect
studi
suggest
strategi
may
effect
chemali
et
al
whether
ribavirin
indic
rsv
uri
remain
controversi
center
includ
author
administ
presenc
lymphopenia
less
per
mm
risk
progress
particularli
high
chemali
et
al
lymphopenia
highli
signific
risk
factor
progress
lower
tract
diseas
first
month
hct
chemali
et
al
data
risk
progress
later
hct
anecdot
experi
author
institut
suggest
factor
poor
lung
function
may
import
patient
prolong
immunosuppress
studi
need
defin
risk
factor
set
small
nonrandom
studi
suggest
palivizumab
given
preemptiv
patient
rsv
uri
prevent
progress
pneumonia
chavezbueno
et
al
prophylact
measur
recommend
throughout
respiratori
viru
season
includ
isol
infect
patient
hand
wash
everi
patient
contact
educ
effort
target
health
care
personnel
famili
member
avoid
patient
contact
health
care
personnel
famili
member
uncontrol
secret
studi
exist
pharmacolog
prophylaxi
rsv
acquisit
pretranspl
infect
rsv
parainfluenzaviru
influenzaviru
transplant
center
postpon
transplant
procedur
resolut
symptom
cessat
viral
shed
especi
myeloabl
allogen
hct
plan
approach
support
recent
studi
pretranspl
rsv
infect
show
rapid
progress
rsv
pneumonia
patient
transplant
procedur
postpon
peck
et
al
howev
evid
lowrisk
autolog
transplant
patient
may
transplant
without
advers
outcom
aslan
et
al
addit
outcom
respiratori
viru
infect
appear
less
sever
nonmyeloabl
reducedtox
condit
regimen
schiffer
et
al
hmpv
newli
discov
negativesens
nonseg
rna
paramyxoviru
van
den
hoogen
et
al
structur
viru
close
relat
rsv
age
virtual
children
seroposit
viru
caus
upper
lower
tract
infect
winter
season
boivin
et
al
seriou
lower
respiratori
tract
diseas
associ
hmpv
report
immunocompromis
patient
risk
factor
acquisit
describ
tabl
hmpv
infect
occur
hct
recipi
figur
whether
asymptomat
shed
occur
controversi
debiaggi
et
al
progress
rate
lower
respiratori
tract
diseas
determin
among
hct
recipi
undergo
bal
clinic
radiograph
pneumonia
hmpv
detect
englund
et
al
patient
previous
classifi
idiopath
pneumonia
syndrom
englund
et
al
hmpv
diseas
hct
recipi
immedi
posttranspl
typic
present
upper
respiratori
symptom
includ
fever
nasal
congest
cough
pneumonia
develop
rapidli
progress
pulmonari
infiltr
frequent
accompani
hypotens
septic
shock
englund
et
al
radiograph
find
rang
diffus
bilater
alveolar
interstiti
infiltr
emphysema
without
infiltr
high
viral
load
observ
bronchoalveolar
lavag
fluid
histolog
assess
show
diffus
alveolar
damag
hyalin
membran
format
foci
bronchiol
obliteran
organ
pneumonia
diffus
alveolar
hemorrhag
common
englund
et
al
date
establish
treatment
hmpv
diseas
may
fatal
hct
recipi
englund
et
al
although
ivig
shown
effect
neutral
hmpv
vitro
effect
vivo
unknown
wyde
et
al
role
steroid
also
defin
ribavirin
shown
vitro
antivir
activ
hmpv
wyde
et
al
howev
report
treatment
ribavirin
infect
control
measur
similar
outlin
rsv
mainstay
prevent
parainfluenza
virus
classifi
four
serotyp
type
parainfluenza
virus
parainfluenzaviru
common
approxim
follow
serotyp
incub
time
day
parainfluenzaviru
infect
remain
detect
throughout
summer
season
even
standard
virolog
method
incid
parainfluenzavirus
higher
rsv
differ
cancer
center
nichol
et
al
pcr
detect
significantli
increas
diagnost
yield
hct
unrel
donor
risk
factor
acquisit
parainfluenzaviru
found
nichol
et
al
cell
deplet
patient
use
lymphopenia
report
increas
risk
respiratori
viru
infect
includ
parainfluenzaviru
infect
chakrabarti
et
al
similar
rsv
hmpv
uri
predomin
clinic
present
tabl
progress
pneumonia
seem
less
common
rsv
nichol
et
al
late
airflow
obstruct
link
parainfluenzaviru
pneumonia
also
uri
erard
et
al
import
risk
factor
progress
uri
pneumonia
use
system
corticosteroid
lymphopenia
chakrabarti
et
al
nichol
et
al
first
month
hct
recipi
nonmyeloabl
condit
regimen
appear
small
risk
progress
lower
respiratori
tract
diseas
chakrabarti
et
al
schiffer
et
al
follow
reduc
intens
condit
regimen
may
also
somewhat
lower
risk
progress
fatal
diseas
chakrabarti
et
al
howev
larger
studi
need
better
defin
risk
progress
although
overal
progress
rate
pneumonia
allograft
recipi
risk
mgkg
prednison
given
treatment
graft
versu
host
diseas
mgkg
nichol
et
al
parainfluenzaviru
pneumonia
may
also
occur
autolog
transplant
howev
mainli
set
select
use
highdos
steroid
nichol
et
al
parainfluenzaviru
pneumonia
associ
seriou
pulmonari
copathogen
aspergillu
fumigatu
approxim
half
case
factor
associ
poor
outcom
pneumonia
includ
presenc
copathogen
mechan
ventil
nichol
et
al
thu
aggress
diagnost
intervent
ie
bal
therapi
indic
patient
suspect
parainfluenzaviru
pneumonia
larg
retrospect
analysi
uri
pneumonia
due
parainfluenzaviru
associ
overal
mortal
multivari
model
nichol
et
al
mortal
pneumonia
approxim
recipi
allograft
follow
myeloabl
condit
nichol
et
al
outcom
appear
somewhat
better
patient
receiv
reduc
toxic
condit
regimen
chakrabarti
et
al
retrospect
analysi
neither
aerosol
ribavirin
intraven
immunoglobulin
led
improv
outcom
pneumonia
reduct
viral
shed
follow
pneumonia
nichol
et
al
system
ribavirin
report
case
report
chakrabarti
et
al
random
treatment
studi
perform
definit
assess
made
whether
earlier
antivir
treatment
ie
preemptiv
treatment
uri
effect
prevent
pneumonia
late
airflow
obstruct
chakrabarti
et
al
associ
highdos
steroid
treatment
progress
diseas
might
suggest
reduct
immunosuppress
may
use
nichol
et
al
howev
approach
test
role
immunoglobulin
treatment
parainfluenzaviru
infect
also
poorli
defin
one
retrospect
analysi
find
benefit
pool
immunoglobulin
given
parainfluenzaviru
pneumonia
nichol
et
al
howev
antibodi
content
pool
prepar
highli
variabl
highest
titer
obtain
rsvspecif
immunoglobulin
also
contain
high
titer
antibodi
direct
parainfluenzaviru
cortez
et
al
infect
control
mainstay
prevent
strategi
unfortun
current
infect
control
practic
seem
far
perfect
keep
parainfluenza
viru
hct
unit
indic
high
incid
figur
repeat
outbreak
cortez
et
al
nichol
et
al
zambon
et
al
possibl
explan
difficulti
prevent
parainfluenzaviru
enter
hct
unit
includ
lack
vaccin
health
care
worker
close
contact
mild
lack
symptom
immunocompet
individu
combin
prolong
shed
prolong
asymptomat
shed
infect
patient
persist
viru
environment
surfac
influenza
classifi
three
major
type
type
common
follow
type
b
bowden
ljungman
et
al
influenza
type
c
uncommon
even
immunocompet
popul
report
influenza
c
hct
recipi
influenza
viru
infect
seem
less
common
rsv
parainfluenza
viru
infect
subtyp
caus
infect
although
type
appear
common
acquisit
influenza
increas
patient
highrisk
underli
diseas
nichol
et
al
progress
sever
pneumonia
occur
similar
rsv
parainfluenzaviru
bowden
howev
progress
rate
appear
lower
risk
factor
progress
differ
tabl
contrast
parainfluenzaviru
infect
corticosteroid
import
risk
factor
develop
pneumonia
influenza
viru
lower
tract
infect
appear
less
common
patient
treat
corticosteroid
machado
et
al
nichol
et
al
also
patient
receiv
nonmyeloabl
condit
regimen
appear
less
like
develop
pneumonia
schiffer
et
al
interestingli
clinic
present
hct
often
lack
myalgia
high
fever
commonli
seen
immunocompet
individu
figur
effect
prevent
avail
influenza
may
explain
lower
incid
health
care
personnel
famili
member
visitor
advis
get
vaccin
influenza
earli
season
antivir
therapi
avail
influenza
viru
infect
howev
avail
agent
studi
systemat
hct
recipi
due
recent
emerg
resist
amantidin
rimantidin
agent
use
treat
prevent
influenza
bright
et
al
neuraminidas
inhibitor
ie
zanamavir
oseltamivir
avail
hayden
et
al
nicholson
et
al
activ
influenza
b
uncontrol
studi
suggest
preemptiv
therapi
neuraminidas
inhibitor
ie
oseltamivir
zanamivir
effect
prevent
progress
lower
tract
diseas
chemali
et
al
johni
et
al
nichol
et
al
widespread
chemoprophylaxi
suscept
immunosuppress
patient
outbreak
situat
recommend
casecontrol
studi
oseltamivir
suggest
approach
safe
hct
recipi
vu
et
al
hrhv
classifi
picornaviru
character
small
nake
singlestrand
rna
approxim
serotyp
usual
caus
mild
upper
respiratori
tract
symptom
immunocompet
host
use
cultur
techniqu
rhinoviru
infrequ
report
caus
respiratori
infect
hct
recipi
howev
sever
report
found
organ
patient
pneumonia
gosh
et
al
report
lower
tract
diseas
patient
rhinoviru
infect
ghosh
et
al
bowden
et
al
document
lower
tract
diseas
infect
patient
bowden
rhinoviru
appear
occasion
caus
lower
respiratori
tract
diseas
gutman
et
al
although
clear
caus
role
sometim
difficult
ascertain
presenc
copathogen
ghosh
et
al
ison
et
al
surveil
studi
use
rtpcr
ongo
order
precis
defin
role
hrhv
hct
recipi
enterovirus
also
picornavirus
transmit
fecalor
respiratori
rout
respiratori
infect
occur
limit
evid
exist
signific
respiratori
pathogen
present
drug
vaccin
avail
treatment
prevent
hrhv
infect
pleconaril
capsidbind
compound
first
antirhinoviru
antivir
submit
fda
regulatori
approv
approv
licensur
treatment
cold
adult
primarili
base
drug
interact
modest
treatment
effect
antivir
agent
includ
proteas
inhibitor
activ
vitro
whether
compound
develop
uncertain
patick
zinc
salt
prepar
echinacea
also
weakli
activ
vitro
metaanalys
shown
benefit
zinc
salt
jackson
et
al
display
moder
effect
echinacea
immunocompet
subject
although
result
consist
turner
et
al
lind
et
al
studi
perform
immunosuppress
patient
compound
hcov
rna
virus
caus
upper
respiratori
infect
croup
wheez
pneumonia
immunocompet
individu
sinc
sever
new
strain
describ
includ
addit
previous
describ
strain
recent
studi
patient
admit
hospit
hcov
detect
hcov
infect
occur
immunocompromis
patient
compar
immunocompet
patient
fourteen
hcovinfect
patient
includ
hct
recipi
also
infect
signific
copathogen
gerna
et
al
hcov
also
detect
solid
organ
transplant
recipi
patient
underli
malign
hivinfect
individu
kumar
et
al
hcov
infect
also
associ
longterm
declin
lung
transplant
recipi
kumar
et
al
surveil
studi
ongo
defin
incid
diseas
associ
hcov
hct
recipi
specif
treatment
hcov
infect
control
measur
recommend
similar
respiratori
virus
hbov
newli
identifi
human
parvoviru
origin
identifi
random
pcr
amplificationclon
techniqu
hospit
children
sweden
alland
et
al
hbov
detect
worldwid
chung
et
al
foulongn
et
al
man
et
al
appear
common
young
children
symptom
associ
hbov
infect
includ
rhinorrhea
cough
fever
wheez
hypoxia
diarrhea
arnold
et
al
date
limit
inform
clinic
signific
hbov
infect
immunocompromis
patient
schenk
et
al
surveil
studi
ongo
better
defin
incid
pathogenesi
hbov
hct
recipi
specif
treatment
hbov
infect
control
measur
recommend
similar
respiratori
virus
adenovirus
categor
subgroup
f
present
human
serotyp
known
serotyp
five
subgroup
caus
diseas
immunocompet
immunocompromis
subject
although
diseas
spectrum
associ
strain
may
differ
bruno
et
al
horwitz
primari
infect
adenoviru
establish
latenc
adenoid
tissu
horwitz
lifelong
persist
specif
antibodi
transmiss
adenoviru
occur
either
respiratori
droplet
oralfec
rout
adenoviru
enter
mucosa
infect
epitheli
cell
result
inflamm
necrosi
subsequ
viremia
may
lead
dissemin
diseas
hct
reactiv
latenc
probabl
problemat
exogen
infect
bruno
et
al
howev
transmiss
via
respiratori
rout
occur
adenoviru
infect
common
hct
recent
report
suggest
may
increas
possibl
relat
transplant
practic
eg
cell
deplet
bruno
et
al
flomenberg
et
al
howev
incid
adenoviru
diseas
depend
degre
immunosuppress
seem
increas
recipi
cell
deplet
graft
flomenberg
et
al
clinic
manifest
includ
pneumonia
hepat
gastrointestin
diseas
nephriti
cystiti
eye
infect
bruno
et
al
bruno
et
al
cox
et
al
flomenberg
et
al
risk
factor
adenoviru
asymptomat
infect
hct
includ
gvhd
unrel
donor
statu
use
total
bodi
irradi
cell
deplet
younger
age
baldwin
et
al
bruno
et
al
flomenberg
et
al
degre
cell
deplet
posttranspl
immunosuppress
direct
cell
function
appear
particularli
import
lion
et
al
almost
studi
report
higher
incid
children
bruno
et
al
wasserman
et
al
adenoviru
endorgan
diseas
commonli
seen
follow
condit
regimen
includ
vivo
ex
vivo
cell
deplet
flomenberg
et
al
risk
factor
adenoviru
diseas
includ
younger
age
howard
et
al
viremia
shed
site
baldwin
et
al
howard
et
al
schilham
et
al
total
bodi
irradi
hale
et
al
gvhd
flomenberg
et
al
transplant
unrel
donor
baldwin
et
al
plasma
viremia
import
risk
factor
diseas
erard
et
al
adenoviru
diseas
associ
fatal
rate
respons
treatment
seem
particularli
poor
patient
pneumonia
dissemin
diseas
ljungman
et
al
recent
multivari
analysi
nont
cell
deplet
hct
recipi
indic
adenoviru
infect
independ
associ
mortal
bruno
et
al
control
treatment
studi
adenoviru
infect
immunocompromis
patient
intraven
ribavirin
use
result
conflict
bordigoni
et
al
chakrabarti
et
al
gavin
katz
lile
et
al
recent
cidofovir
shown
vitro
activ
sever
uncontrol
case
seri
show
promis
result
legrand
et
al
ljungman
et
al
neofyto
et
al
yusuf
et
al
sivaprakasam
et
al
ganciclovir
vitro
activ
adenoviru
moder
effect
prevent
adenoviru
infect
nont
cell
deplet
patient
bruno
et
al
howev
treatment
adenoviru
diseas
ganciclovir
recommend
antiretrovir
drug
zalzitabin
ddc
alovudin
stavudin
activ
vitro
naesen
et
al
uchio
et
al
differ
vitro
suscept
treatment
outcom
result
studi
may
due
strain
serotyp
differ
often
report
studi
specif
nonspecif
cell
therapi
report
small
seri
chakrabarti
et
al
feuchting
et
al
leen
et
al
regn
et
al
highrisk
set
haploident
transplant
cord
blood
transplant
weekli
pcr
surveil
adenoviru
viremia
preemptiv
treatment
cidofovir
use
sever
center
lion
et
al
yusuf
et
al
howev
strategi
complet
elimin
adenoviru
diseas
highestrisk
patient
yusuf
et
al
even
though
cidofovir
initi
viral
load
detect
cellreplet
transplant
recipi
plasma
dnaemia
greater
copiesml
correl
well
presenc
adenoviru
diseas
erard
et
al
level
preemptiv
antivir
therapi
initi
depend
pcr
assay
perform
characterist
underli
immunosuppress
latter
determin
vivo
viral
dynam
time
definit
threshold
establish
howev
repeat
test
day
low
viral
load
test
identifi
patient
rapid
increas
viral
load
use
adenovirusspecif
cell
prevent
treatment
adenoviru
diseas
area
activ
research
feuchting
et
al
random
trial
need
evalu
prevent
strategi
recommend
summar
cdcidsaasbmt
revis
document
expect
publish
earli
hand
wash
singl
effect
way
prevent
spread
respiratori
virus
perform
patient
contact
health
care
personnel
visitor
respiratori
isol
use
hct
recipi
document
respiratori
viru
infect
well
upper
respiratori
symptom
diagnost
workup
period
mask
gown
glove
eye
protect
one
area
uncertainti
lift
isol
patient
becom
asymptomat
persist
lowlevel
shed
detect
molecular
method
extent
patient
contagi
present
unknown
virus
known
caus
seriou
diseas
ie
rsv
parainfluenzavirus
influenzavirus
hmpv
appear
prudent
isol
patient
posit
pcr
even
asymptomat
whether
necessari
virus
extrem
uncommon
unclear
diseas
associ
eg
hrhv
hcov
present
area
activ
research
ubiquit
use
mask
among
health
care
worker
famili
member
asymptomat
patient
remain
controversi
one
nonrandom
studi
suggest
benefit
mask
raad
et
al
howev
question
remain
type
mask
frequenc
chang
mask
wear
mask
transplant
center
univers
mask
polici
recent
cdc
guidelin
recommend
use
mask
patient
transport
anoth
approach
like
reduc
transmiss
restrict
health
care
worker
famili
member
patient
contact
uri
system
symptom
rhinorhea
wateri
eye
sneez
fever
myalgia
nichol
et
al
peck
et
al
uniformli
done
adult
patient
center
restrict
small
children
direct
patient
contact
respiratori
viru
season
due
predisposit
uri
prolong
hightit
shed
strategi
restrict
access
personnel
close
contact
effect
infect
present
signific
drainag
symptom
rsv
rhinoviru
hmpv
influenza
infect
parainfluenzaviru
infect
may
present
mild
symptom
may
miss
approach
nichol
et
al
respiratori
virus
recogn
caus
pneumonia
late
airflow
obstruct
hct
although
major
progress
made
understand
diseas
associ
develop
diagnost
test
major
gap
remain
one
gap
avail
sensit
specif
inexpens
multiplex
diagnost
platform
detect
relev
respiratori
virus
optim
import
bacteri
pathogen
well
fortun
develop
test
method
advanc
method
establish
allow
studi
diseas
associ
also
essenti
develop
therapeut
option
immunosuppress
also
immunocompet
subject
one
key
reason
slow
progress
drug
develop
absenc
widespread
officebas
test
nichol
et
al
systemat
comprehens
evalu
diseas
burden
infect
also
need
histor
pneumonia
death
report
howev
data
airflow
obstruct
health
care
util
includ
durat
hospit
intens
care
mechan
ventil
import
well
anoth
area
need
diseas
pathogenesi
although
sever
studi
point
toward
lymphopenia
import
risk
factor
sever
manifest
diseas
exact
host
defens
mechan
lead
devast
consequ
respiratori
viru
infect
hct
recipi
virtual
unknown
studi
import
viru
load
cell
humor
immun
well
cytokin
chemokin
express
genet
need
date
studi
focu
earli
period
transplant
inform
need
risk
progress
outcom
late
hct
ie
first
month
lymphopenia
rare
may
birect
relationship
respiratori
virus
lung
function
late
transplant
viral
infect
may
lead
prolong
airflow
obstruct
preexist
airflow
obstruct
may
predispos
individu
progress
lower
tract
diseas
poor
outcom
also
limit
knowledg
determin
risk
viru
acquisit
studi
ongo
determin
whether
genet
predisposit
furthermor
major
progress
need
regard
treatment
option
respiratori
virus
except
treatment
influenza
viru
potent
easi
administ
drug
treatment
develop
novel
treatment
prevent
option
rsv
highest
prioriti
exist
option
ribavirin
palivizumab
polyclon
antibodi
prepar
moder
efficaci
complic
give
often
prohibit
expens
especi
given
adult
patient
sever
lead
compound
current
evalu
nichol
et
al
recent
establish
volunt
infect
model
could
speed
drug
vaccin
develop
devincenzo
et
al
past
difficult
conduct
random
clinic
trial
rsv
hct
recipi
howev
failur
complet
trial
directli
link
level
complex
requir
give
aerosol
ribavirin
novel
antivir
compound
easi
administ
requir
hospit
lack
seriou
side
effect
highli
feasibl
conduct
clinic
trial
hct
set
anoth
unmet
medic
need
treatment
option
parainfluenzaviru
preval
respiratori
virus
known
diseas
associ
nichol
et
al
also
well
design
prospect
observ
studi
need
defin
diseas
burden
recent
discov
respiratori
virus
novel
coronavirus
human
bocaviru
polymavirus
final
even
today
see
symptomat
patient
unabl
make
virolog
diagnosi
despit
multiplex
pcr
test
thu
probabl
see
addit
yet
discov
respiratori
virus
futur
monthli
distribut
rsv
parainfluenza
viru
influenza
infect
hct
fhcrc
permiss
time
first
respiratori
viru
infect
hct
obtain
permiss
symptom
associ
respiratori
viru
infect
hct
obtain
permiss
tabl
respiratori
viru
infect
hct
comparison
rsv
parainfluenzaviru
influenzavirus
winter
season
incid
may
high
mayb
significantli
higher
outbreak
martino
et
al
season
symptom
diagnosi
respiratori
virus
immunocompet
subject
hct
recipi
adapt
nichol
et
al
